{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:12:15Z","timestamp":1789420335328,"version":"build-2803163510"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011096","name":"Philippine Council for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Human adenovirus (HAdV), particularly the HAdV type 5 (HAdV-5), has been extensively utilized in the development of vector vaccines due to its high immunogenicity, good safety profile, and ease of propagation. However, one of the main challenges in its use is the presence of pre-existing immunity among vaccine recipients. Pre-existing neutralizing antibodies (NAbs) can prevent the uptake of HAdV-5 vectors and reduce vaccine efficacy. Hence, this study investigated the seroprevalence of NAbs against HAdV-5 in urban and rural regions of the Philippines. Luciferase-based neutralization assay was performed on 391 plasma\/serum samples. Out of these samples, 346 or 88.5% were positive for HAdV-5 NAbs, and the majority of them (56.8%) had high titers against the virus. Among the regions included in this study, Bicol (Region V) had the highest seroprevalence rate (94.1%). Our findings show that a significant number of adults in the Philippines have pre-existing immunity against HAdV-5. This supports the recommendation that vaccination programs in the country should consider implementing vaccination techniques, such as a prime-boost regimen or addition of booster doses, to address the potential negative effects of pre-existing HAdV-5 immunity in the efficacy of adenoviral vector-based vaccines.<\/jats:p>","DOI":"10.1371\/journal.pone.0293046","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:36:29Z","timestamp":1701455789000},"page":"e0293046","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines"],"prefix":"10.1371","volume":"18","author":[{"given":"Abialbon G.","family":"Francisco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Carlo B.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Kim B.","family":"Tabios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Criselda Jean G.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Angelo C.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M.","family":"Heralde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita Racquel G.","family":"Lacuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5598-3951","authenticated-orcid":true,"given":"Sheriah Laine M.","family":"de Paz-Silava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"pone.0293046.ref001","volume-title":"Jawetz melnick & adelberg\u2019s medical microbiology","author":"Geo Brooks","year":"2012","edition":"26"},{"issue":"2","key":"pone.0293046.ref002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/v15020330","article-title":"An Old Acquaintance: Could Adenoviruses Be Our Next Pandemic Threat?","volume":"15","author":"G Saint-Pierre Contreras","year":"2023","journal-title":"Viruses"},{"key":"pone.0293046.ref003","unstructured":"cdc.gov. Center for Disease Control and Prevention; c2022 [cited 2022 November 28]. Available from: https:\/\/www.cdc.gov\/adenovirus\/index.html."},{"issue":"6","key":"pone.0293046.ref004","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00705-016-2804-0","article-title":"Genetic variability of human adenovirus type 8 causing epidemic and sporadic cases of keratoconjunctivitis","volume":"161","author":"N Fedaoui","year":"2016","journal-title":"Arch Virol"},{"issue":"6","key":"pone.0293046.ref005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jmv.24022","article-title":"Viral gastroenteritis in children in Colorado 2006\u20132009","volume":"87","author":"CM Osborne","year":"2015","journal-title":"J Med Virol"},{"issue":"1","key":"pone.0293046.ref006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1086\/518442","article-title":"Molecular epidemiology of adenovirus type 4 infections in US military recruits in the post vaccination era (1997\u20132003)","volume":"196","author":"AE Kajon","year":"2007","journal-title":"J Infect Dis"},{"issue":"7","key":"pone.0293046.ref007","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1086\/653612","article-title":"Outbreak of adenovirus type 4 infection in a long-term care facility for the elderly","volume":"31","author":"R Kandel","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"pone.0293046.ref008","article-title":"Surveillance of airborne adenovirus and Mycoplasma pneumoniae in a hospital pediatric department","volume":"7","author":"G. H. Wan","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"pone.0293046.ref009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/biomedicines7030061","article-title":"Perspective on Adenoviruses: Epidemiology, Pathogenicity, and","volume":"7","author":"BJ Crenshaw","year":"2019","journal-title":"Gene Therapy. Biomedicines"},{"issue":"4","key":"pone.0293046.ref010","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"N Tatsis","year":"2004","journal-title":"Mol Ther"},{"issue":"6","key":"pone.0293046.ref011","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"WS Wold","year":"2013","journal-title":"Curr Gene Ther"},{"issue":"10","key":"pone.0293046.ref012","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"H Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"9653","key":"pone.0293046.ref013","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"pone.0293046.ref014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"G Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"pone.0293046.ref015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","article-title":"A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults","volume":"29","author":"JE Ledgerwood","year":"2010","journal-title":"Vaccine"},{"issue":"13","key":"pone.0293046.ref016","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-\u03b3 T cell responses in humans","volume":"31","author":"W Peters","year":"2013","journal-title":"Vaccine"},{"issue":"205","key":"pone.0293046.ref017","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"F Smaill","year":"2013","journal-title":"Sci Transl Med"},{"issue":"10255","key":"pone.0293046.ref018","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"DY Logunov","year":"2020","journal-title":"Lancet"},{"issue":"10240","key":"pone.0293046.ref019","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"FC Zhu","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"pone.0293046.ref020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.virusres.2004.05.003","article-title":"Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture","volume":"105","author":"DS Bangari","year":"2004","journal-title":"Virus Res"},{"issue":"4","key":"pone.0293046.ref021","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","author":"M. Echavarr\u00eda","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"pone.0293046.ref022","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Z Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"pone.0293046.ref023","volume-title":"Adenoviruses","author":"S Singh","year":"2019"},{"issue":"Pt 6","key":"pone.0293046.ref024","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1099\/0022-1317-73-6-1429","article-title":"Antipeptide antisera define neutralizing epitopes on the adenovirus hexon","volume":"73","author":"CI Toogood","year":"1992","journal-title":"J Gen Virol"},{"issue":"10","key":"pone.0293046.ref025","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"DH Barouch","year":"2004","journal-title":"J Immunol"},{"issue":"11","key":"pone.0293046.ref026","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"DR Casimiro","year":"2003","journal-title":"J Virol"},{"issue":"9","key":"pone.0293046.ref027","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00144-09","article-title":"Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults","volume":"16","author":"C Harro","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"pone.0293046.ref028","volume-title":"Reports of suspected adverse reaction to COVID-19 vaccines (01 March 2021 to 30 April 2023)","author":"Philippine Food and Drug Administration","year":"2023"},{"issue":"11","key":"pone.0293046.ref029","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"MC Sprangers","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"8","key":"pone.0293046.ref030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"JX Li","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"12","key":"pone.0293046.ref031","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"S Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10249","key":"pone.0293046.ref032","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"FC Zhu","year":"2020","journal-title":"Lancet"},{"key":"pone.0293046.ref033","unstructured":"psa.gov.ph. Philippine Statistics Authority; c2023 [cited 2023 31 October]. Available from https:\/\/psa.gov.ph\/system\/files\/phdsd2023-01\/3-Highlights%2520of%2520the%25202021%2520Full%2520Year%2520Official%2520Poverty%2520Statistics%252C%252012Aug2022_0.pdf."},{"key":"pone.0293046.ref034","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-7091-1818-4_8","article-title":"Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines","volume":"16","author":"AV Borovjagin","year":"2014","journal-title":"Novel Technologies for Vaccine Development"},{"issue":"4","key":"pone.0293046.ref035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"TC Mast","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"pone.0293046.ref036","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"B Yu","year":"2012","journal-title":"J Med Virol"},{"issue":"7","key":"pone.0293046.ref037","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1086\/342573","article-title":"Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies","volume":"35","author":"SA Kolavic-Gray","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pone.0293046.ref038","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1086\/340502","article-title":"Age-related decrease in adenovirus-specific T cell responses","volume":"185","author":"M Sester","year":"2002","journal-title":"J Infect Dis"},{"issue":"5","key":"pone.0293046.ref039","doi-asserted-by":"crossref","first-page":"e37532","DOI":"10.1371\/journal.pone.0037532","article-title":"Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China","volume":"7","author":"Q Liu","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"pone.0293046.ref040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jmv.23546","article-title":"Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults","volume":"85","author":"S Zhang","year":"2013","journal-title":"J Med Virol"},{"issue":"10","key":"pone.0293046.ref041","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"AR Thorner","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"22","key":"pone.0293046.ref042","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1016\/j.vaccine.2011.03.042","article-title":"Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China","volume":"29","author":"C Sun","year":"2011","journal-title":"Vaccine"},{"issue":"32","key":"pone.0293046.ref043","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"DH Barouch","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"pone.0293046.ref044","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jmv.21721","article-title":"The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines","volume":"82","author":"R Pilankatta","year":"2010","journal-title":"J Med Virol"},{"issue":"46","key":"pone.0293046.ref045","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1016\/j.vaccine.2016.09.043","article-title":"Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions","volume":"34","author":"WX Yang","year":"2016","journal-title":"Vaccine"},{"issue":"9","key":"pone.0293046.ref046","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"P Abbink","year":"2007","journal-title":"J Virol"},{"issue":"2","key":"pone.0293046.ref047","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/vaccines11020432","article-title":"Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status","volume":"11","author":"VP Chavda","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"Pt 1","key":"pone.0293046.ref048","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","article-title":"Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor","volume":"83","author":"CJ Cohen","year":"2002","journal-title":"J Gen Virol"},{"issue":"115","key":"pone.0293046.ref049","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"S Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"pone.0293046.ref050","unstructured":"doh.gov.ph. Philippines Department of Health; c2023 [cited 2023 August 24]. Available from https:\/\/doh.gov.ph\/covid19tracker."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:37:11Z","timestamp":1701455831000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293046"}},"subtitle":[],"editor":[{"given":"Ralph A.","family":"Tripp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293046","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}